Literature DB >> 1551953

Biological characterization of the naturally occurring analogues of intrapituitary human follicle-stimulating hormone.

A Ulloa-Aguirre1, A Cravioto, P Damián-Matsumura, M Jiménez, E Zambrano, V Díaz-Sánchez.   

Abstract

In the present studies we analysed the main physicochemical and biological properties of the several isoforms of human pituitary follicle-stimulating hormone (hFSH). Extracts of total anterior pituitary glycoproteins from adult donors were submitted to chromatofocusing and several forms of immunoactive hFSH with isoelectric points (pI) ranging from 7.6 to 3.8 were identified. An additional isoform was detected after passing through the chromatofocusing column a 1.0 M NaCl solution (salt peak). Each hFSH isoform or pool of neighbouring isoforms (pI value 7.6-7.1, pool I, 1.5 +/- 0.13% of total immunoactivity recovered; pI value 5.9-5.3, pool II, 8.9 +/- 1.6% of total; pI value 5.0-4.7, pool III, 14.4 +/- 1.4% of total; pI value 4.5-4.1, pool IV, 54.8 +/- 4.9% of total; pI value 3.9-3.8, pool V, 3.67 +/- 0.9% of total; salt peak, pool VI, 16.8 +/- 4.8% of total) eluted as single hFSH peaks after Sephadex G-100 exclusion chromatography (apparent Mr 60,000). Even though hFSH present within each pool was recognized by a receptor preparation, the receptor-binding activity expressed as the radioreceptor assay:radioimmunoassay (RRA/RIA) activity ratio varied with the pI value of the particular hFSH isoform tested; starting from a pI value of 5.9, the receptor-binding activity of hFSH decreased from 4.25 +/- 0.28 to 1.17 +/- 0.14, as the pI value of the corresponding isoform declined. A similar trend was observed when the potency of each isoform was assessed by an in vitro bioassay.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551953     DOI: 10.1093/oxfordjournals.humrep.a137550

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  10 in total

1.  Efficacy of a combined protocol of urinary and recombinant follicle-stimulating hormone used for ovarian stimulation of patients undergoing ICSI cycle.

Authors:  Arianna Pacchiarotti; Cesare Aragona; Renzo Gaglione; Helmy Selman
Journal:  J Assist Reprod Genet       Date:  2007-07-26       Impact factor: 3.412

2.  Receptor binding activity and in vitro biological activity of the human FSH charge isoforms as disclosed by heterologous and homologous assay systems: implications for the structure-function relationship of the FSH variants.

Authors:  E Zambrano; T Zariñán; A Olivares; J Barrios-de-Tomasi; A Ulloa-Aguirre
Journal:  Endocrine       Date:  1999-04       Impact factor: 3.633

3.  Molecular composition of two different batches of urofollitropin: analysis by immunofluorimetric assay, radioligand receptor assay and in vitro bioassay.

Authors:  M Simoni; G F Weinbauer; E Nieschlag
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

Review 4.  Role of glycosylation in function of follicle-stimulating hormone.

Authors:  A Ulloa-Aguirre; C Timossi; P Damián-Matsumura; J A Dias
Journal:  Endocrine       Date:  1999-12       Impact factor: 3.633

5.  Biological activity and metabolic clearance of recombinant human follicle stimulating hormone produced in Sp2/0 myeloma cells.

Authors:  C K Chin; P R Schofield; D M Robertson; P P Gray; W Chotigeat; S M Mahler
Journal:  Cytotechnology       Date:  1996-06       Impact factor: 2.058

6.  Hypo-glycosylated human follicle-stimulating hormone (hFSH(21/18)) is much more active in vitro than fully-glycosylated hFSH (hFSH(24)).

Authors:  George R Bousfield; Vladimir Y Butnev; Viktor Y Butnev; Yasuaki Hiromasa; David J Harvey; Jeffrey V May
Journal:  Mol Cell Endocrinol       Date:  2013-12-01       Impact factor: 4.102

7.  A mathematical model for the actions of activin, inhibin, and follistatin on pituitary gonadotrophs.

Authors:  Richard Bertram; Yue-Xian Li
Journal:  Bull Math Biol       Date:  2008-08-09       Impact factor: 1.758

Review 8.  Profile of follitropin alpha/lutropin alpha combination for the stimulation of follicular development in women with severe luteinizing hormone and follicle-stimulating hormone deficiency.

Authors:  Leonardo Rinaldi; Helmy Selman
Journal:  Int J Womens Health       Date:  2016-05-25

9.  Comparative pharmacology of a new recombinant FSH expressed by a human cell line.

Authors:  Wolfgang Koechling; Daniel Plaksin; Glenn E Croston; Janni V Jeppesen; Kirsten T Macklon; Claus Yding Andersen
Journal:  Endocr Connect       Date:  2017-04-27       Impact factor: 3.335

10.  Basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution and in vitro biological-to-immunological ratio in male puberty.

Authors:  A Olivares; D Söderlund; C Castro-Fernández; T Zariñán; Elena Zambrano; J P Méndez; A Ulloa-Aguirre
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.925

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.